Skip to main content
SpringerLink
Log in

Hohe Ansprechraten für Erdafitinib bei Patienten mit FGFR-mutiertem Urothelkarzinom nach Versagen einer platinbasierten Chemotherapie

High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Uniklinik-Dresden, Haus 27, Fetscherstr. 74, 01307, Dresden, Deutschland

    C. Grülllich

Authors
  1. C. Grülllich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Grülllich.

Ethics declarations

Interessenkonflikt

C. Grülllich gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grülllich, C. Hohe Ansprechraten für Erdafitinib bei Patienten mit FGFR-mutiertem Urothelkarzinom nach Versagen einer platinbasierten Chemotherapie. Urologe 59, 478–479 (2020). https://doi.org/10.1007/s00120-020-01160-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-020-01160-6

Search

Navigation